BioScrip (NASDAQ:BIOS) announced its quarterly earnings data on Tuesday. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by ($0.02), Briefing.com reports. The company had revenue of $181.00 million during the quarter, compared to analyst estimates of $171.35 million. During the same period last year, the company posted ($0.12) EPS. The company’s quarterly revenue was down 8.9% compared to the same quarter last year. BioScrip updated its FY 2018 guidance to $-0.32–0.26 EPS.
Shares of NASDAQ:BIOS traded up $0.37 during midday trading on Tuesday, hitting $3.18. 19,687 shares of the stock were exchanged, compared to its average volume of 345,857. BioScrip has a 52-week low of $1.88 and a 52-week high of $3.26. The firm has a market cap of $361.09 million, a price-to-earnings ratio of -7.25 and a beta of 0.42.
Several analysts recently issued reports on the company. BidaskClub upgraded BioScrip from a “buy” rating to a “strong-buy” rating in a report on Friday, September 21st. Zacks Investment Research lowered BioScrip from a “buy” rating to a “hold” rating in a report on Monday, August 6th. Finally, Barrington Research reiterated a “buy” rating and set a $4.00 price objective on shares of BioScrip in a report on Wednesday, August 8th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. BioScrip currently has an average rating of “Buy” and a consensus price target of $3.56.
Large investors have recently made changes to their positions in the stock. Rhumbline Advisers raised its holdings in BioScrip by 16.9% during the second quarter. Rhumbline Advisers now owns 126,878 shares of the company’s stock valued at $372,000 after buying an additional 18,372 shares in the last quarter. Bank of America Corp DE raised its holdings in BioScrip by 8.5% during the second quarter. Bank of America Corp DE now owns 243,794 shares of the company’s stock valued at $714,000 after buying an additional 19,096 shares in the last quarter. Metropolitan Life Insurance Co. NY raised its holdings in BioScrip by 77.3% during the second quarter. Metropolitan Life Insurance Co. NY now owns 45,013 shares of the company’s stock valued at $132,000 after buying an additional 19,625 shares in the last quarter. Mesirow Financial Investment Management Inc. raised its holdings in BioScrip by 24.3% during the second quarter. Mesirow Financial Investment Management Inc. now owns 114,541 shares of the company’s stock valued at $336,000 after buying an additional 22,382 shares in the last quarter. Finally, BlackRock Inc. raised its holdings in BioScrip by 0.5% during the first quarter. BlackRock Inc. now owns 6,617,126 shares of the company’s stock valued at $16,277,000 after buying an additional 33,021 shares in the last quarter. Institutional investors and hedge funds own 84.99% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright legislation. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/11/06/bioscrip-bios-releases-quarterly-earnings-results-misses-expectations-by-0-02-eps.html.
BioScrip Company Profile
BioScrip, Inc provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.
Recommended Story: Yield Curve
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.